-

, ... ..

 -

.
6000
5000
4000
3000

2000
1000
0
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012


- ,
-
,
,
6090 % .
:

-
-

- , ,
-
- , ,
-

,

,
.

,
,


:

(, , ,
) .
:
( ;
, . ),
,
.


(2533% )
6%
.
50%
, 40% -
10% - .
80% .

1.

2.

3.
4.

5.

6.
,

3
6

,
D .

2 ,
D.

6 ,

Y-
, 2+;
.

1
.
- ,
,
.

9 12

,
,
.

, -

,
;
;
.

, ;
, ,
( 15% ).

, ;

, ().

( , ),
,
.
, .

[Donovan UM, 1995; Lowe NM., 2002].


[Freudenheim JL.
1986; Angus RM, 1988], [Elmstahl S, 1998;
Hyun T.H., 2004].
(10 /) 53%

.

,
,

,
.. ,
, ,
,
,

-
,
, 2 255 753 2005
2 599 860 2011 ( 15,3%)

2012 ,
24

25 %.

99 %
,
.
21 %
.

25 %.

 :
- ,
( 20%)
( 55%) ;
- 35% ;
-
-
.

: , , , -
, - , .

( 23%) ( 7%)

,
:
- , 1, 2, 6, , -;
- : , , ;
- : , , , , ;
- .

60-80% ,

1, 2, 6, - 40-80%,
40% .

70 % -
:
(3[Ca3(PO4)] Ca(OH)2), , ,
, , .

30 % - :


50 % ,
28,15% -

( 16%
),
21,85%-
.

,


,



(
10 )

 VOSEPOS 600
50 (300 300
)

.. . . ... - . . ., 2001.

,
,

,
,

( )

(, )

(, )
(,
, )
(, )
(, , )

FK506 ()
(, )

- (-)

(, )

 :

( 4-5 %

)
, ( 45 )



.
:
(

,
)
( ,


)

( )

 :
.

,
.
,
, .

,
.

- ,

.
,
,

.


-
+2,0 1

1,0 2,5

1:

D,

2:

3:

D,

2,5

2,5
4: , 2,

FRAX

,
() .)


(75%)

(25%)

,

..


(, ,

..)

/
()

(, , )




-

 ?
.
?
.

-6
,
D, , , , ,



( 3 )
( 3 )



I

1-1,5 /

(0,6-0,8 /)

[Kerstetter JE, 1998, 2000]

( 2 /)

.
50
60
[Kerstetter JE, 1994; Munger RG, 1999]

(
): ,
, , , ,
, , ,
, , ,
, .

(): , ,
, , , , ,
(, ), , ,
.


389 ,
,
D D 54 .
/2

Marini H. ., 2007.

- 14





,

Xu M. , Osteoporosis Int., 2009, 20 (4), 519-526.


, ( 5

) 3 .

, ( 5

( ,

(1000- 1500 /)

D (800 /)

).

) -

, ,

. T-
1, .
.

 D


.

,
,

.

 D
(, ):

25()D3 32 /.
Heany .: 65%
, 25()D3
34 /.
D
10-15%,
D
30-40%.


25()D3

150 /

70 /

40 /
0 /

JJ. Cannell, BW. Hollis Alternative Medicine Review Vol.13, N 1 2008

 D
- ,
,
, .
Broe .: 72%
5
800 D.
Bischof-Ferrari .: 49%
, 800
D3 1200 ,
,
1200 .


French Decalyos
I Study
French Decalyos
II Study5
British Study of
Vitamin D and
Osteoporotic
Fracture Study
Boston Area Study

Japanese study of
sunlight exposure on
BMD & hip fracture
Japanese study of
hip fracture
reduction

(.)

3270 (1762-54%) .
18 .
800 .D3 + 1,2 . 2+
()
610
2
800 .D3 + 1,2 . 2+
()
2 686
65-85 (66%)
5
100 000 .D3/4 . per os
389 (318-82%)
, . . 74
3
700 .D3 + 500 .2+
( )
258
12
50% - 15
/. , 50%
264 .
12
- 1,2 . /,
50% - 15
/. , 50%

%
25()D3

./.
32%
16 / 42 /

43%
9 / 30 /

31-38%

4 - 29
/ ..,
21 /- .
.

33%

60%

30 / 44 /
60%

6
. .
6,8 / 20,8 / 3,3%

3,1% . .
4-
(3/11)
9,6 / 20,8 / (2 /9)
5,6%
2,7% . .

10-15




10 000 D

!
D

, , ,
, ,
, .
D
,
35
.
, (42 ) D
4
. -,
D,
. -
.
6 .

 10
- 310 %,

,

. 30
2-3 .
:
,
,
, D, .
, .

 . . . , . 20, 3 (. 1), 2009

10
16 ,


15
US Department of Health and Human Services.
Healthy People 2010. 2nd ed. Washington, DC:
Government Printing Office; 2000.

D
/100
100

30
20,5

17,5

16,3
12

20/10%

0,12/0,08

30%

0,15

1,5

2,2-7,7

, , ,
, , ,

0-0,02

24-40
1
1%


1996-2003 .
400 /

401-525 /

526-700 /

701 /

100%
80%
60%

23,8

23,9

25,3

25,3

26,2

24,6

15,9

15,3

15,9

15,9

16,7

16,3

16,4

16,2

16,4

16,4

15,9

15,8

43,9

47,7

42,4

42,4

41,2

43,3

1996

1998

2000

2001

2002

2003

40%
20%
0%

.. . , ,2005,
5, . 14-18.

 (
/)

18-30

> 56

1994 513 (+378) 581 (+424) 461 (+341) 540 (+427) 466 (+317)
1996

540
627 (+418) 475 (+307) 553 (+376) 518 (+347)
(+367)
1998 503 (+329) 572 (+363) 452 (+290) 530 (+361) 481 (+314)

2000 542 (+372) 618 (+418) 486 (+329) 559 (+391) 523 (+352)

2002

560
634 (+441) 507 (+330) 558 (+390) 562 (+372)
(+380)
2003 543 (+543) 616 (+413) 490 (+318) 531 (+366) 555 (+358)

.. . , ,2005,
5, . 14-18.



, /
6 .
15
610

( 11 24 )
2550

400
600
8001200
12001500

1000

2565

1000

65

1500

1000
12001500
1500

(/ 100
)

(/100
)

(/100
)

1290

245

120

920

()

230

100

890

230

100

850

220

( )

85

(,
..)

750

210

80

670

200

70

(
)

500

170

55

280

()

145

55

( )

35

(
)

260

136

257

125

70%

73%

, ,

16%

14%

6-7%

12%

7-8%

2000
500
500
500

1
1
2
3

2000
500
250
167

14%
29%
36%
40%

280
145
180
200,5

,
,
, , , , ,
.

.
( 1500 /)
D (200-400 /)
, D,
.
, ,
, , .

,
, .
,
.
, 4-6- .
, 2-3 .

( , ,
, ,
.).

 ,
,
( , ),

85-90
110-120

70-80
80-90

300-330
2170-2400
250-350
2080-2690

 () ,

(, , ) (, , ,
)

( , , .)

, - ,

;
;
;
.

( 60 )

( )
).

) , ,
,
(, , , ..)

(, , ,

/, ..)

,

.


,



,

,
, ,

0,5-1 % ( 5 % )
3

30-35

Hegen M. . Ann Rheum Dis, 67, 2008, 1505-1515.

(,

).

:

( ,
)
(,
).

II
I, III, X .

,
(1,
) (,
,
2),
.

, , ,

.


0
1
2
3
4
5
6

15
15

30

1 ,
500 - 300 - 100 -

1

900 500 300 100

1-4-
5-7-
8-10 -

11-13 -
14 -




, ,
( )

" "
,

,
,
,

.. Consilium Medicum, . 06/N 12/2004 .

.
,
3-5 ,

( , ,
..)

:
(,

)

(

:
/

, ,

, , , ,
, ,
.

.

(
1,2 : 1)

W-6 W-3.


.


(,
, , , ,
) 2 .

, ( , , , -).

, ,
.

(
) ,
.

(
5-6 ).

, , ,
,

85-90

70-80

300-330

2170-2400

110-120

80-90

250-350

2080-2690

20-60

80-90

350-400

2120-2650

70-80

60-70

130-150

1340-1550

. ,
, ,
, ,
, , ,
.
.
( .
.
. . .

). .
. .
(
. .
. .
.
-.
).

. ,
, , ,
(, ), ,
.

.
.
, , ,
, .
2 . :
(4-6 /), , ,
: , , , , ,
, , , .

(, , ).
, ,.
- 60-65, - 15.
- 2,5 (
). , 4-6
.
: - 85-90 , .. 40-45 , 70-80 , .. 25-30 , - 300-330
(
), - 25 .
, , , , . 2170-2400 .

.
.
.
. .
.
. .
. .
. .

. ,
,
.

() .
(6-8 /), ,
. , ,
, , .
- 15 60-65 . - 1,5-2 .
, 4-6 .
: - 110-120 , .. 45-50 ;
-80-90 , .. 30 ; 300-350 , - 25 . 20802690 . , , , , .

.

.

.


.
. 0,8
0,6 0,3 / ( 60, 40 20 /),
(1,5-3 /)
(0,8-1 ). ,
, , , , .
, , ,
. ,
, , .
, . ,
. - 0,8-1,0 .
, 4-6 .
: - 2060 , 1530
; - 80-90 , - 20-30 ;
- 350-400 , 50-100 ,
- 15-20 . 2120-2650 .

. , ,
,
.
.

,
, .

() .
(35 /).
, , ,
, . - 15 6065. - 0,8-1,5 .
, 4-6 .
: - 70-80 , .. 40 ;
- 60-70 , .. 25 ;
- 130-150 , - 30-40 .
1350-1550 .

-

-
-

-3

- - (, ,
)
- ( ,
)
,

(,
, ) (, , , )

( , , , -)

, ( )

 .
.

.

.
,
.

(
).

:

().
: ,

,
.
,
, .
.
: 5-6 ,
- .
:

- 70-80 (50 % ),
- 80-90 (30 % ),
- 400 (80 ),
- 27002800;
10 ,
- 1,5-2 .

, ;
;
, ;
, ;
;
, , ,
, , ;
- , , ;
, , - 2-3 .

: ,
, , , , ,
, , , , , ,
, , , , , ,
, , , , ,
.
B1.

MSM

SAMe

:Zn, Ca, Mg, Mn,

Cu, Si, Fe, Se,

, , D, K.

-3,

 ;
;
;
-3;
;
.

S-

(SAMe)

HerreroBeaumont
(2005)

(GUIDE)
trial.

n=

318 1500 /
3000

24

Bruyere (2004) 414 1500 /

3

.

Pavelka (2002) 202

1500 /
3
.
.

Reginster (2001) 212

1500 /
3
.
.

( )
/ ().
/

( )
/ ().

/

,


.

,
,
. ,
II
.

-1:



.

NO .

O
O

OH

O
O

S OH
O

HO

OH

O
OH

H3C

HN
O

N <40

0,3 5,3 /.


200%,
2
4
.

Volpi N. Osteoarthritis Cartilage. 2002

Oct;10(10):768-77.


( ,
..)
3
119
%

40

30

35
30
25
20
15

8,8

10
5

p<0.001

0
1200

Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting
drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis
Cartilage. 1998;6(suppl A):3136.


6
85

100
90

80

%
69

70
60
50
40

32

400 2 \

30
20

p<0.001

10
0
Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting
drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis
Cartilage. 1998;6(suppl A):3136.

n=

Michel . 300
800 /
2
(2005)
.
(

) /
.
().
Uebelhar 120
800 /
2
t (2004)
.
3
(

) /
.
().

/
Mazieres 130 3000 /
3

(2001)
.

/
.

 :

.








,

 +
.

n=

Clegg
(2005)

158
3

1500 +1200
/ 200
,
.
.

24

/
/

Das and
Hammad
(2004)

93

2000 +1600
/ 304

Leffler
(2001)

130

3000 /
.
.

16

(GAIT)
trial

732
, :

(
2 )
4 SAMe (1200 )
,
,

Caruso I, Am J Med. 1987;83(5A):6671.

Najm WI
. BMC Musculoskelet Disord.2004;5:6.

118
-
(500 3 /)

(500 3 /),

. Usha P.R., Naidu M.U.R.
Randomised, double-blind, parallel, placebo-controlled study of
oral glucosamine, methylsulfonylmethane and their combination
in osteoarthritis. Clinical Drug Investigation. 2004;24:353-363.

260

300 600 / 3

(
)
.
. Appelboom T, Schuermans J,
Verbruggen G, et al. Scand J Rheumatol. 2001;30:242247.

, ,
, ,


, , CD44, TLR4, ICAM1,
:

(
), ,
,
.

Alexander G SchaussFASEB J.April 2008

22 (Meeting Abstract Supplement) 729

(Minozzi, M., 2010;
Tindara La Galia, 2014).

40 , 3 ,
, ,
.

60 , 12 , , 200 .

70
.

26 , 12 , 1 2 ,
.
76%, , 13,2%,
6,3%.

 .., , 15, 8, 2007 .

1957


.

4,0
9,8.
per os
40% 1
.

 -

(, ,
)
,

-
-

45-60
-

( )

- ,

.


0
1
2
3
4
5
6

15
15

30

1 ,
500 - 300 - 100 -

1

900 500 300 100

100
80
60
%
40
20
0

200

400

o WOMAC
Walker AF . Phytomedicine. 2002 Dec;9(8):681-6.

-3

N ()

Aloe vera,
Liliaceae
Camellia sinensis,
Theaceae
Withania somnifera,

3
4
(
)

, ,
,

, .. ,
, -,
, ,

( ), (
)

,

5 ,

Boswellia carterii,

Curcuma longa,

Zingiber officinale,
(

),

A REVIEW ON PLANTS HAVING ANTI-ARTHRITIC POTENTIAL Arya V, Gupta VK , Kaur R

International Journal of Pharmaceutical Sciences Review and Research V7, Is2,
March - April 2011; Article-024

11

Comarum palustre,

Eugenia caryaphyllata,

12

Ginkgo biloba,

Harpagophytum

procumbens,

15
(
,
)
19

,
,
,

Smilax corbularia,
Liliaceae
20 Uncaria tomentosa,
Rubiaceae
21 (, Commiphora mukul,
) Burseraceae

27

Vitis vinifera, Vitaceae

,

Z E, I-V,
;
,

, ,
, ,
, ,

3

(Kremer JM, 1985; Cleland LG, 1988)

3,
2.
3
(-
-1)


, ,

59% 250


3 1,5-5 /
(Maroon
JC, Bost JW: Omega-3 fatty acids (fish oil) as an
antiinflammatory: an alternative to nonsteroidal antiinflammatory drugs for discogenic pain. Surg Neurol
65:326331, 2006.)

 , ,
, .
! :

15- :

E-mail: